Comparative effectiveness of sotrovimab and molnupiravir for preventing severe COVID-19 outcomes in patients on kidney replacement therapy: observational study using the OpenSAFELY-UKRR and SRR databases.
Bang ZhengJacqueline CampbellEdward J CarrJohn TazareLinda NabViyaasan MahalingasivamAmir MehrkarShalini SanthakumaranRetha SteenkampFiona LoudSusan LyonMiranda ScanlonWilliam J HulmeAmelia C A GreenHelen J CurtisLouis FisherEdward ParkerAlex J WalkerIan DouglasStephen EvansBrian MacKennaSamira BellLaurie A TomlinsonDorothea Nitschnull nullPublished in: Clinical kidney journal (2023)
In routine care of non-hospitalised patients with COVID-19 on KRT, sotrovimab was associated with a lower risk of severe COVID-19 outcomes compared with molnupiravir during Omicron waves.
Keyphrases
- replacement therapy
- coronavirus disease
- sars cov
- end stage renal disease
- ejection fraction
- healthcare
- newly diagnosed
- chronic kidney disease
- early onset
- palliative care
- smoking cessation
- prognostic factors
- peritoneal dialysis
- type diabetes
- clinical practice
- quality improvement
- machine learning
- big data
- artificial intelligence
- deep learning